Literature DB >> 31788936

Loss of ANCO1 repression at AIB1/YAP targets drives breast cancer progression.

Max H Kushner1, Virginie Ory1, Garrett T Graham1, Ghada M Sharif1, William B Kietzman1, Sophia Thevissen2, Meng Yuan1, Marcel O Schmidt1, Anton Wellstein1, Anna T Riegel1.   

Abstract

Transcription factors critical for the transition of normal breast epithelium to ductal carcinoma in situ (DCIS) and invasive breast cancer are not clearly defined. Here, we report that the expression of a subset of YAP-activated and YAP-repressed genes in normal mammary and early-stage breast cancer cells is dependent on the nuclear co-activator AIB1. Gene expression, sequential ChIP, and ChIP-seq analyses show that AIB1 and YAP converge upon TEAD for transcriptional activation and repression. We find that AIB1-YAP repression of genes at the 1q21.3 locus is mediated by AIB1-dependent recruitment of ANCO1, a tumor suppressor whose expression is progressively lost during breast cancer progression. Reducing ANCO1 reverts AIB1-YAP-dependent repression, increases cell size, and enhances YAP-driven aberrant 3D growth. Loss of endogenous ANCO1 occurs during DCIS xenograft progression, a pattern associated with poor prognosis in human breast cancer. We conclude that increased expression of AIB1-YAP co-activated targets coupled with a loss of normal ANCO1 repression is critical to patterns of gene expression that mediate malignant progression of early-stage breast cancer.
© 2019 The Authors.

Entities:  

Keywords:  1q21.3; AIB1; ANCO1; YAP; ductal carcinoma in situ

Mesh:

Substances:

Year:  2019        PMID: 31788936      PMCID: PMC6945057          DOI: 10.15252/embr.201948741

Source DB:  PubMed          Journal:  EMBO Rep        ISSN: 1469-221X            Impact factor:   8.807


  60 in total

1.  Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10.

Authors:  H D Soule; T M Maloney; S R Wolman; W D Peterson; R Brenz; C M McGrath; J Russo; R J Pauley; R F Jones; S C Brooks
Journal:  Cancer Res       Date:  1990-09-15       Impact factor: 12.701

2.  Yes-associated protein expression in paired primary and local recurrent breast cancer and its clinical significance.

Authors:  Nianhua Ding; Ting Huang; Jiaqi Yuan; Jie Mao; Yumei Duan; Weihua Liao; Zhi Xiao
Journal:  Curr Probl Cancer       Date:  2019-01-17       Impact factor: 3.187

3.  MRTF potentiates TEAD-YAP transcriptional activity causing metastasis.

Authors:  Tackhoon Kim; Daehee Hwang; Dahye Lee; Jeong-Hwan Kim; Seon-Young Kim; Dae-Sik Lim
Journal:  EMBO J       Date:  2016-12-27       Impact factor: 11.598

4.  The transcriptional co-activator TAZ interacts differentially with transcriptional enhancer factor-1 (TEF-1) family members.

Authors:  William M Mahoney; Jeong-Ho Hong; Michael B Yaffe; Iain K G Farrance
Journal:  Biochem J       Date:  2005-05-15       Impact factor: 3.857

5.  The nuclear receptor coactivator amplified in breast cancer-1 is required for Neu (ErbB2/HER2) activation, signaling, and mammary tumorigenesis in mice.

Authors:  Mark P Fereshteh; Maddalena T Tilli; Sung Eun Kim; Jianming Xu; Bert W O'Malley; Anton Wellstein; Priscilla A Furth; Anna T Riegel
Journal:  Cancer Res       Date:  2008-05-15       Impact factor: 12.701

6.  Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth.

Authors:  Francesca Zanconato; Mattia Forcato; Giusy Battilana; Luca Azzolin; Erika Quaranta; Beatrice Bodega; Antonio Rosato; Silvio Bicciato; Michelangelo Cordenonsi; Stefano Piccolo
Journal:  Nat Cell Biol       Date:  2015-08-10       Impact factor: 28.824

7.  A YAP/TAZ-induced feedback mechanism regulates Hippo pathway homeostasis.

Authors:  Toshiro Moroishi; Hyun Woo Park; Baodong Qin; Qian Chen; Zhipeng Meng; Steven W Plouffe; Koji Taniguchi; Fa-Xing Yu; Michael Karin; Duojia Pan; Kun-Liang Guan
Journal:  Genes Dev       Date:  2015-06-15       Impact factor: 11.361

8.  Inactivation of the Hippo tumour suppressor pathway by integrin-linked kinase.

Authors:  Isabel Serrano; Paul C McDonald; Frances Lock; William J Muller; Shoukat Dedhar
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

9.  GeneHancer: genome-wide integration of enhancers and target genes in GeneCards.

Authors:  Simon Fishilevich; Ron Nudel; Noa Rappaport; Rotem Hadar; Inbar Plaschkes; Tsippi Iny Stein; Naomi Rosen; Asher Kohn; Michal Twik; Marilyn Safran; Doron Lancet; Dana Cohen
Journal:  Database (Oxford)       Date:  2017-01-01       Impact factor: 3.451

10.  YAP repression of the WNT3 gene controls hESC differentiation along the cardiac mesoderm lineage.

Authors:  Conchi Estarás; Hui-Ting Hsu; Ling Huang; Katherine A Jones
Journal:  Genes Dev       Date:  2017-12-21       Impact factor: 11.361

View more
  10 in total

1.  One repressor to rule them all: ANCO1 links YAP and AIB1.

Authors:  Can Zhang; Kenneth Moberg
Journal:  EMBO Rep       Date:  2019-12-02       Impact factor: 8.807

Review 2.  Endocrine resistance in breast cancer: from molecular mechanisms to therapeutic strategies.

Authors:  Ozge Saatci; Kim-Tuyen Huynh-Dam; Ozgur Sahin
Journal:  J Mol Med (Berl)       Date:  2021-10-08       Impact factor: 4.599

Review 3.  The biology of YAP in programmed cell death.

Authors:  Yifan Cheng; Misha Mao; Yong Lu
Journal:  Biomark Res       Date:  2022-05-23

Review 4.  SRC-3, a Steroid Receptor Coactivator: Implication in Cancer.

Authors:  Licen Li; Chu-Xia Deng; Qiang Chen
Journal:  Int J Mol Sci       Date:  2021-04-30       Impact factor: 5.923

5.  Phosphorylation of steroid receptor coactivator-3 (SRC-3) at serine 857 is regulated by the p38MAPK-MK2 axis and affects NF-κB-mediated transcription.

Authors:  Anup Shrestha; Henrike Bruckmueller; Hanne Kildalsen; Gurjit Kaur; Matthias Gaestel; Hilde Ljones Wetting; Ingvild Mikkola; Ole-Morten Seternes
Journal:  Sci Rep       Date:  2020-07-09       Impact factor: 4.379

6.  Metastasis-suppressor NME1 controls the invasive switch of breast cancer by regulating MT1-MMP surface clearance.

Authors:  Philippe Chavrier; Mathieu Boissan; Catalina Lodillinsky; Laetitia Fuhrmann; Marie Irondelle; Olena Pylypenko; Xiao-Yan Li; Hélène Bonsang-Kitzis; Fabien Reyal; Sophie Vacher; Claire Calmel; Olivier De Wever; Ivan Bièche; Marie-Lise Lacombe; Ana Maria Eiján; Anne Houdusse; Anne Vincent-Salomon; Stephen J Weiss
Journal:  Oncogene       Date:  2021-05-19       Impact factor: 9.867

7.  Spatial collagen stiffening promotes collective breast cancer cell invasion by reinforcing extracellular matrix alignment.

Authors:  Karin A Jansen; Antoine Khalil; Peter D Haughton; Thijs Koorman; Daan Visser; Max A K Rätze; Wisse E Haakma; Gabrielè Sakalauskaitè; Paul J van Diest; Johan de Rooij; Patrick W B Derksen
Journal:  Oncogene       Date:  2022-03-15       Impact factor: 8.756

8.  AIB1 is a novel target of the high-risk HPV E6 protein and a biomarker of cervical cancer progression.

Authors:  Jonathan Miller; Aleksandra Dakic; Megan Spurgeon; Francisco Saenz; Bhaskar Kallakury; Bo Zhao; Junran Zhang; Jian Zhu; Qin Ma; Ying Xu; Paul Lambert; Richard Schlegel; Anna T Riegel; Xuefeng Liu
Journal:  J Med Virol       Date:  2022-04-27       Impact factor: 20.693

9.  An AIB1 Isoform Alters Enhancer Access and Enables Progression of Early-Stage Triple-Negative Breast Cancer.

Authors:  Ghada M Sharif; Moray J Campbell; Apsra Nasir; Surojeet Sengupta; Garrett T Graham; Max H Kushner; William B Kietzman; Marcel O Schmidt; Gray W Pearson; Olivier Loudig; Susan Fineberg; Anton Wellstein; Anna T Riegel
Journal:  Cancer Res       Date:  2021-06-16       Impact factor: 12.701

10.  17‑AAG synergizes with Belinostat to exhibit a negative effect on the proliferation and invasion of MDA‑MB‑231 breast cancer cells.

Authors:  Yu Zuo; Heng Xu; Zhifeng Chen; Fengmin Xiong; Bei Zhang; Kaixian Chen; Hualiang Jiang; Cheng Luo; Hao Zhang
Journal:  Oncol Rep       Date:  2020-03-26       Impact factor: 3.906

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.